CurrentUnitedHealthcarePolicy 2026T0052OO

Airway Clearance Devices Medical Policy

UnitedHealthcare Commercial and Individual Exchange medical policy governing medical necessity, coverage, and evidence considerations for airway clearance devices including high-frequency chest wall oscillation (HFCWO) systems, intrapulmonary percussive ventilation (IPV), and combination oscillation/lung expansion devices. This part (1 of 2) includes coverage rationale, definitions, evidence summaries, and applicable procedure/diagnosis codes.

Policy Summary

PayerUnitedHealthcare

PolicyAirway Clearance Devices Medical Policy

Policy CodePolicy 2026T0052OO

Change TypeRevisions to coverage criteria and documentation requirements

Effective DateMar 1, 2026

Next Review Date

Key ActionProviders must initiate an initial 2-month rental trial of an HFCWO system to confirm individual tolerance and efficacy prior to determination of ongoing medical necessity; use InterQual criteria for ongoing coverage and include required documentation.

POLICY UPDATE CHANGES

Updated language pertaining to medical necessity clinical coverage criteria for a high-frequency chest wall oscillation (HFCWO) system.

Added required medical records documentation items: results of all recent relevant imaging and diagnostic testing, comorbidities, and for continuation beyond the two-month trial include proper use.

Removed items from medical records documentation: current prescription from physician and CT scan report confirming diagnosis of bronchiectasis if applicable.

Replaced wording 'failed standard treatments to adequately mobilize retained secretions' with 'treatments tried, failed, or contraindicated to adequately mobilize retained secretions; include the dates, duration, and reason for discontinuation'.

Revised description for ICD-10 diagnosis code G35.C2.

Updated Description of Services, Clinical Evidence, and References sections; removed Benefit Considerations section.

Archived previous policy version 2026T0052NN.

Coverage Summary

Policy Number: 2026T0052OO; Effective/Last Review Date: March 1, 2026.

Scope: UnitedHealthcare Commercial and Individual Exchange medical policy governing medical necessity, coverage, and evidence considerations for airway clearance devices including high-frequency chest wall oscillation (HFCWO) systems, intrapulmonary percussive ventilation (IPV), and combination oscillation/lung expansion devices (part 1 of 2 which includes coverage rationale, definitions, evidence summaries, and applicable codes).

High-level coverage summary: HFCWO is covered for an initial 2-month rental trial and is proven and medically necessary for management of neuromuscular diseases, bronchiectasis, and cystic fibrosis when criteria are met; ongoing use requires meeting InterQual durable medical equipment airway/secretion clearance criteria. IPV (home use) and combination OLE devices are considered unproven and not medically necessary (mixed coverage stance).

Key thresholds and quick facts

Cough Peak Flow (PCF) thresholdless than 270 L/minute

Maximal expiratory pressure thresholdless than 60 cm H2O

Initial rental trial duration2 months

Medical-Necessity Criteria

Coverage Rationale - HFCWO

Covered when ALL of the following are met:

ALL of the following

Initial 2-month rental trial of a high-frequency chest wall oscillation (HFCWO) system is used to confirm individual tolerance and efficacy before ongoing medical necessity determination
Providers must initiate an initial 2-month rental trial prior to determination of ongoing medical necessity per policy and provider actions
Indication is one of: neuromuscular diseases, Bronchiectasis, or cystic fibrosis
Policy lists these as proven and medically necessary when criteria are met
Additional ongoing medical necessity criteria as defined by InterQual Client Defined, CP: Durable Medical Equipment, Airway or Secretion Clearance Devices (Custom) - UHG are met
Click referenced InterQual criteria for details

Not Medically Necessary / Unproven

The following are considered unproven and not medically necessary:

ref':'b2_0','title':'Not Medically Necessary / Unproven'

ref_error_fixing_duplicate_keys_fixing? I corrected ref values but kept original format

Noncovered / Insufficient Evidence Statements

Not supported or insufficient evidence statements captured in policy narrative:

ref':'b2_1'}]},

Coding

Durable Medical Equipment / Supplies HCPCSHCPCS

A7021	Supplies and accessories for lung expansion airway clearance, continuous high frequency oscillation, and nebulization device (e.g., handset, nebulizer kit, biofilter).
A7025	High frequency chest wall oscillation system vest, replacement for use with patient-owned equipment, each.
A7026	High frequency chest wall oscillation system hose, replacement for use with patient-owned equipment, each.
E0469	Lung expansion airway clearance, continuous high frequency oscillation, and nebulization device.
E0481	Intrapulmonary percussive ventilation system and related accessories.
E0483	High frequency chest wall oscillation system, with full anterior and/or posterior thoracic region receiving simultaneous external oscillation, includes all accessories and supplies, each

Relevant Diagnosis Codes (examples listed)ICD-10

A80.0	Acute paralytic poliomyelitis, vaccine-associated.
A80.1	Acute paralytic poliomyelitis, wild virus, imported.
A80.2	Acute paralytic poliomyelitis, wild virus, indigenous.
A80.30	Acute paralytic poliomyelitis, unspecified.
A80.39	Other acute paralytic poliomyelitis.
A80.4	Acute nonparalytic poliomyelitis.
A80.9	Acute poliomyelitis, unspecified.
B91	Sequelae of poliomyelitis.
E74.02	Pompe disease.
E74.4	Disorders of pyruvate metabolism and gluconeogenesis.

1–10 of 61

1/7

Applicable Diagnosis (ICD-10) codes referenced/updatedICD-10

G35.C2

ICD-10 diagnosis code description revised in policy (description text in policy revised)

FDA Product Code (informational)mixed

BYI	FDA product code for High-Frequency Chest Wall Compression Devices (informational)

Provider Actions

Prior Authorization

Initial 2-month rental trial requirement

An initial 2-month rental trial of a high-frequency chest wall oscillation (HFCWO) system is required to confirm individual tolerance and clinical benefit before ongoing coverage is considered. Ongoing medical necessity for continued rental or purchase after the 2-month trial must meet InterQual® Client Defined, CP: Durable Medical Equipment, Airway or Secretion Clearance Devices (Custom) - UHG criteria. Affected HCPCS/CPT codes: E0483, E0469, A7021, A7025, A7026. Providers should include the InterQual determination documentation when submitting requests for continuation of coverage following the 2-month trial.

Affected codes: E0483, E0469, A7021, A7025, A7026
Initial rental trial duration: 2 months (required)
Reference for ongoing coverage: InterQual® Durable Medical Equipment, Airway or Secretion Clearance Devices (Custom) - UHG

Documentation Required

Required medical records for review

Background & Evidence

Airway clearance therapies address inadequate mucociliary clearance and retained secretions in conditions such as cystic fibrosis, bronchiectasis, and neuromuscular disease; when coughing alone is insufficient, other therapies are used to mobilize secretions.

Device types and mechanisms summarized: HFCWO — an inflatable vest connected to an air-pulse generator that rapidly inflates/deflates the vest (up to ~20 times/second) to externally oscillate the chest wall and lower mucus viscosity; indicated when external chest manipulation is the physician's treatment of choice.

IPV — intrapulmonary percussive ventilation delivers internal mini-bursts of gas (high-frequency percussions, >200/min) via a mouthpiece to mobilize endobronchial secretions and treat patchy atelectasis.

PEP and conventional chest physical therapy (CCPT) — positive expiratory pressure techniques and manual percussion/postural drainage used to augment cough and secretion clearance; evidence quality varies.

OLE (combination oscillation and lung expansion) — devices combining continuous PEP, continuous high-frequency oscillation, and nebulized medication for oscillation and lung expansion; currently considered unproven and not medically necessary due to insufficient consistent evidence.

Clinical context: these modalities are applied across cystic fibrosis, bronchiectasis, and neuromuscular disease populations to improve expectoration, reduce exacerbations/hospitalizations, or augment cough, but evidence strength and recommended roles differ by device and indication.

Study / Source	Key Findings
HFCWO - Meta-analysis (Huang 2022)
In AECOPD, HFCWO increased expectorated sputum volume by 6.18 mL and shortened hospital stay by 4.37 days; no significant improvement in FEV1, PaO2, PaCO2; notable heterogeneity and limitations noted.
Registry cohort (Barto 2020)
In non-cystic fibrosis bronchiectasis registry (n=2,596), initiation of HFCWO was associated with reduced hospitalizations and antibiotic use and improved self-reported respiratory health and airway clearance over 1 year.
Lechtzin 2016 cohort
In individuals with neuromuscular disease (n=426), total medical costs, hospitalizations, and pneumonia claims decreased after initiation of HFCWO.
Cochrane/Pooled evidence (McIlwaine 2019)
PEP vs other ACTs: mixed evidence; PEP with a mask reduced exacerbations versus other techniques including HFCWO in long-term trials; evidence quality variable.
CCPT vs alternatives
No difference in FEV1 percent predicted or rate of decline between CCPT and alternative ACTs; overall evidence very low certainty across many comparisons.
OLE (Huynh et al. 2019)
OLE reduced postoperative pulmonary complications (22.9% to 15.8%) and reduced ventilator time and hospital length of stay in a prospective study (p<0.05).
IPV RCT (Hassan et al. 2024)
In nonventilated critically ill patients, IPV reduced median ICU length of stay (3.5 vs 5.2 days; MD 1.56 days; p=0.002) and improved oxygenation and respiratory rate.
Systematic reviews (Morrison & Milroy 2020; Reychler 2018; others)
Multiple systematic reviews conclude low or very low quality evidence; no clear superiority of oscillatory devices over other ACTs and call for adequately powered RCTs.
HFCWO RCTs and cohort studies (Nicolini 2013; Leemans 2020; Fitzgerald 2014)
Small RCTs and cohort studies show mixed short-term improvements in sputum expectoration, some lung function and quality-of-life measures, but limitations include small sample sizes and short follow-up.

Bronchiectasis: A chronic respiratory disease confirmed radiographically (CT) with clinical manifestations of recurrent, chronic, or refractory infections and clinically significant disease defined by at least two of: cough most days, sputum production most days, or history of exacerbations.

Revision History

2026-03-01material_revisionLatest

is_material: true — Updated language pertaining to medical necessity clinical coverage criteria for a high-frequency chest wall oscillation (HFCWO) system; replaced InterQual reference with InterQual Client Defined, CP: Durable Medical Equipment, Airway or Secretion Clearance Devices (Custom) - UHG; archived previous policy version 2026T0052NN. (change text: Updated language pertaining to medical necessity clinical coverage criteria for a high-frequency chest wall oscillation (HFCWO) system.; detail: Replaced reference to InterQual client-defined durable medical equipment secretion clearance devices with InterQual Client Defined, CP: Durable Medical Equipment, Airway or Secretion Clearance Devices (Custom) - UHG.)

2026-03-01material_revisionLatest

is_material: true — Revised Medical Records Documentation Used for Reviews: added required items results of all recent relevant imaging and diagnostic testing, comorbidities, and for continuation beyond the two-month trial include proper use. (change text: Added required medical records documentation items: results of all recent relevant imaging and diagnostic testing, comorbidities, and for continuation beyond the two-month trial include proper use.; detail: )